XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
Preprint
- 8 May 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Currently, there is limited knowledge about the molecular mechanisms of the "non-canonical" Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are key molecules in this signaling pathway, may be an effective approach to treating hematologic tumors. Methods: Cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not epithelial cells. It effectively inhibits the growth of B- and T-cell tumors by blocking cell cycle progression mainly during the G2/M phase, inducing apoptosis and autophagy. Under XMU-MP-1 treatment, caspase 3/7 activity increases and the level of cleaved PARP protein increases. The protein level of LC3-II also increases, while the level of p62 decreases. These changes are associated with apoptosis and autophagy, respectively. RNA-Seq analysis demonstrated that XMU-MP-1 suppresses the expression of cell cycle regulators, such as E2F and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2; cyclin dependent kinases. At the same time, it increases the expression of genes involved in apoptosis, autophagy, and necroptosis. Additionally, XMU-MP-1 enhances the effects of doxorubicin, making it a potential candidate for combination therapy in cancer treatment. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapies of hematological tumors.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- The two sides of Hippo pathway in cancerSeminars in Cancer Biology, 2022
- The Hippo Signaling Pathway in Development and DiseaseDevelopmental Cell, 2019
- YAP/TAZ at the Roots of CancerCancer Cell, 2016
- MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathwayNature Communications, 2015
- YAP and TAZ: a nexus for Hippo signaling and beyondTrends in Cell Biology, 2015
- Spatial Organization of Hippo Signaling at the Plasma Membrane Mediated by the Tumor Suppressor Merlin/NF2Cell, 2013
- The Sterile 20-like Kinase Tao-1 Controls Tissue Growth by Regulating the Salvador-Warts-Hippo PathwayDevelopmental Cell, 2011
- Tao-1 Phosphorylates Hippo/MST Kinases to Regulate the Hippo-Salvador-Warts Tumor Suppressor PathwayDevelopmental Cell, 2011
- The human tumour suppressor LATS1 is activated by human MOB1 at the membraneBiochemical and Biophysical Research Communications, 2006
- Induction of autophagy and inhibition of tumorigenesis by beclin 1Nature, 1999